Relacorilant(Relacorilant) - 药物靶点：GR_在研适应症：库欣综合征，腹膜癌，铂耐药性输卵管癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Relacorilant (USAN)

靶点

GR

作用方式

拮抗剂

作用机制

GR拮抗剂(糖皮质激素受体拮抗剂)

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病+ [2]

在研适应症

库欣综合征腹膜癌铂耐药性输卵管癌+ [10]

非在研适应症

转移性胰腺导管腺癌

原研机构

Corcept Therapeutics, Inc.

在研机构

Corcept Therapeutics, Inc.

非在研机构-

权益机构-

最高研发阶段申请上市

首次获批日期-

最高研发阶段(中国)-

特殊审评孤儿药 (欧盟)

登录后查看时间轴

结构/序列

分子式C27H22F4N6O3S

InChIKeyWANIDIGFXJFFEL-SANMLTNESA-N

CAS号1496510-51-0

关联

24

项与 Relacorilant 相关的临床试验

NCT06906341

/ Recruiting临床2期

A Phase 2 Study of Relacorilant in Combination With Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (BELLA)

This is a Phase 2, single-arm, open-label study to evaluate efficacy and safety of intermittent dosing of relacorilant in combination with nab-paclitaxel and bevacizumab in patients with ovarian cancer.

开始日期2025-04-11

申办/合作机构

Corcept Therapeutics, Inc.

NCT05726292

/ Recruiting临床2期IIT

A Randomized Phase II Trial of Neoadjuvant Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as hormone therapy. This study is for individuals who have been diagnosed with advanced, high-risk prostate cancer and standard therapies available to treat your disease have not been effective. Participation in this research will last about 3 years and 9 months.

开始日期2025-01-06

申办/合作机构

The University of Chicago

NCT05257408

/ Active, not recruiting临床3期

A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel Versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)

The primary objectives of this study are to evaluate progression-free survival (PFS) by blinded independent central review (BICR) and overall survival (OS) (evaluated independently, as dual primary endpoints) in patients treated with intermittent regimen of Relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel monotherapy.

开始日期2022-06-29

申办/合作机构

Corcept Therapeutics, Inc.

[+1]

100 项与 Relacorilant 相关的临床结果

登录后查看更多信息

100 项与 Relacorilant 相关的转化医学

登录后查看更多信息

100 项与 Relacorilant 相关的专利（医药）

登录后查看更多信息

35

项与 Relacorilant 相关的文献（医药）

2024-11-04·The Oncologist

Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study

Article

作者: Borazanci, Erkut H ; Leal, Alexis D ; Oberstein, Paul E ; Huyck, Timothy K ; Mann, Grace ; Bahary, Nathan ; Chiorean, Elena Gabriela ; Fountzilas, Christos ; Hanna, Wahid T ; Cardin, Dana B ; Chung, Vincent ; Kio, Ebenezer A ; Pashova, Hristina ; Lee, Valerie ; Alese, Olatunji B ; Skeel, Roland T ; Noonan, Anne M ; Wainberg, Zev A ; Philip, Philip A

AbstractBackgroundModulation of glucocorticoid receptor (GR) activity in tumor cells enhances chemotherapy efficacy. We evaluated the selective GR modulator relacorilant plus nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who had received at least 2 prior therapy lines.Patients and MethodsIn this open-label, single-arm, phase III study, patients received once-daily oral relacorilant (100 mg, titrated to 150 mg in 25 mg increments/cycle) and nab-paclitaxel (80 mg/m2) on days 1, 8, and 15 of 28-day cycles. The primary efficacy endpoint was objective response rate (ORR) by blinded independent central review. Progression-free survival (PFS), overall survival (OS), target gene modulation, and safety were also assessed.ResultsOf 43 patients enrolled, 31 were evaluable for ORR (12 did not reach first postbaseline radiographic assessment). An interim analysis to assess whether ORR was ≥10% showed no confirmed responses and the study was discontinued. Two (6.5%) patients attained unconfirmed partial responses and 15 (48.4%) had stable disease. Fourteen of 31 (45.2%) patients had reductions in target lesion size, despite prior nab-paclitaxel exposure in 12 of the 14. Median PFS and OS were 2.4 months (95% CI, 1.4-4.2) and 3.9 months (95% CI, 2.8-4.9), respectively. The most common adverse events were fatigue and nausea. RNA analysis confirmed that relacorilant plus nab-paclitaxel suppressed 8 cortisol target genes of interest.ConclusionRelacorilant plus nab-paclitaxel showed modest antitumor activity in heavily pretreated patients with mPDAC, with no new safety signals. Studies of this combination in other indications with a high unmet medical need are ongoing.

2024-08-02·Expert Review of Anticancer Therapy

Relacorilant in recurrent ovarian cancer: clinical evidence and future perspectives

Review

作者: Sassu, Carolina Maria ; Ghizzoni, Viola ; Fagotti, Anna ; Marchetti, Claudia ; Giudice, Elena ; Salutari, Vanda ; Vertechy, Laura ; Carbone, Maria Vittoria ; Scambia, Giovanni

INTRODUCTIONRelacorilant (CORT125134, Corcept Therapeutics) is a selective glucocorticoid receptor modulator, which reverses the glucocorticoid-mediated anti-apoptotic effects and restores the taxane chemosensitivity in epithelial ovarian cancer cells. Given those preclinical findings, relacorilant is currently under investigation in clinical trials in combination with nab-paclitaxel for the platinum-resistant ovarian cancer setting.AREAS COVEREDAlready published preclinical and clinical evidence of relacorilant antitumor activity was analyzed and discussed. Ongoing clinical trials registered on clincaltrials.gov were also reported. The review aimed to summarize the status of relacorilant, the mechanism of action, the published and ongoing trials, and its safety and efficacy.EXPERT OPINIONRelacorilant combined with nab-paclitaxel, may represent a promising strategy for the treatment of platinum-resistant ovarian cancer patients. After preliminary positive results in terms of clinical efficacy, a randomized phase III trial is ongoing to confirm the findings from the published phase II study.

2024-06-03·Clinical Cancer Research

A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer

Article

作者: Sweis, Randy F. ; Stadler, Walter M. ; O'Donnell, Peter H. ; Szmulewitz, Russell Z. ; Desai, Kunal B. ; Serritella, Anthony V.

AbstractPurpose:The majority of patients with metastatic prostate cancer who receive androgen-deprivation therapy and androgen receptor (AR) signaling inhibitors (ARSI) progress. Activation of the glucocorticoid receptor (GR) is associated with ARSI resistance. This single-arm phase I trial assessed safety and pharmacokinetic (PK) feasibility of a combined AR antagonist (enzalutamide) and selective GR modulator (relacorilant) in patients with metastatic castration-resistant prostate cancer (mCRPC).Patients and Methods:This was a phase I trial (NCT03674814) of relacorilant and enzalutamide in patients with refractory mCRPC enrolled using a 6+3 design. The enzalutamide dose was kept constant at 120 mg/d with escalating doses of relacorilant based on safety and PK measures in cohorts of ≥6 patients. The primary objective was safety and establishment of pharmacologically active doses. Secondary objectives were related to antitumor activity.Results:Thirty-five patients with mCRPC were enrolled. Twenty-three were accrued across three dose cohorts in the dose-escalation phase, and 12 enrolled at the recommended phase II dose. The combination was generally well tolerated, safe, and achieved desirable enzalutamide PK. RP2D of 120 + 150 mg/d, respectively, was established. Median time on study was 2.2 months with four patients remaining on study for longer than 11 months. Four of 12 evaluable patients had a prostate-specific antigen (PSA) partial response.Conclusions:This is the first prospective trial combining an AR antagonist and a nonsteroidal selective GR modulator. The combination was safe and well tolerated with PSA response and prolonged disease control observed in a limited subset of patients. Further prospective trials are justified to evaluate efficacy and identify predictive biomarkers of response.

48

项与 Relacorilant 相关的新闻（医药）

2025-04-26

·微信

ASCO 2025丨一文了解妇科肿瘤口头报告

点上方蓝字“ioncology”关注我们，然后点右上角“…”菜单，选择“设为星标”ASCO 2025 微专辑扫描二维码可查看更多内容2025年美国临床肿瘤学年会（ASCO 2025）将于5月30-6月3日在美国芝加哥举行。日前，ASCO公布了本次大会的摘要题目和大会日程，本刊整理了妇科肿瘤领域的口头报告专场（Oral Abstract Session）和快速口头报告（Rapid Oral Abstract Session）专场标题，供读者参考。口头报告专场TRUST: Trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33/AGO‐OVAR OP7).TRUST：晚期卵巢癌根治性前期手术治疗试验（ENGOT ov33/AGO‐OVAR OP7）汇报者：Sven Mahner丨慕尼黑路德维希马克西米利安大学医院摘要号：LBA5500Sentinel lymph node biopsy versus pelvic lymphadenectomy in cervical cancer: The PHENIX trial宫颈癌前哨淋巴结活检 vs 盆腔淋巴结清扫术对比：PHENIX试验汇报者：刘继红丨中山大学肿瘤防治中心摘要号：LBA5501Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in locally advanced cervical cancer (LACC): Phase 3 CALLA trial analyses.循环肿瘤DNA（ctDNA）超灵敏检测和追踪及其与局部晚期宫颈癌患者复发和生存的关系：III期CALLA试验分析汇报者：Jyoti Mayadev丨加州大学圣地亚哥医学中心摘要号：5502Patient-reported outcomes (PROs) in locally advanced cervical cancer (LACC): Insights from the OUTBACK trial.OUTBACK试验中局部晚期宫颈癌的患者报告结局(PRO) 汇报者：Linda R. Mileshkin丨彼得·麦卡勒姆癌症中心摘要号：5503Pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer: Final analysis results of the phase 3, randomized, double-blind ENGOT-cx11/GOG-3047/KEYNOTE-A18 study.帕博利珠单抗联合放化疗治疗高危局部晚期宫颈癌患者：III期随机双盲ENGOT-cx11/GOG-3047/KEYNOTE-A18 研究的最终分析结果汇报者：Linda R. Duska丨弗吉尼亚大学医学院摘要号：LBA5504FIRST/ENGOT-OV44: A phase 3 clinical trial of dostarlimab (dost) and niraparib (nira) in first-line (1L) advanced ovarian cancer (aOC).FIRST/ENGOT-OV44：dostarlimab和尼拉帕利一线治疗晚期卵巢癌的III期临床试验汇报者：Anne-Claire Hardy-Bessard丨Armoricain肿瘤中心摘要号：LBA5506ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72).ROSELLA：评估relacorilant+白蛋白结合型紫杉醇vs.白蛋白结合型紫杉醇单药治疗铂耐药卵巢癌的III期研究（GOG-3073、ENGOT-ov72）汇报者：Alexander Olawaiye丨匹兹堡大学医学院和麦吉妇女医院摘要号：LBA5507Benmelstobart plus carboplatin/paclitaxel with or without anlotinib, followed by maintenance benmelstobart with or without anlotinib, as first-line treatment for advanced or recurrent endometrial cancer: A randomized, open-label, phase II trial. 贝莫苏拜单抗联合卡铂/紫杉醇±安罗替尼，随后贝莫苏拜单抗±安罗替尼维持治疗用于晚期或复发性子宫内膜癌一线治疗：一项随机、开放标签、II期临床试验汇报者：陈晓军丨上海市第十人民医院摘要号：5508 快速口头摘要专场Cadonilimab plus platinum-based chemotherapy ± bevacizumab for persistent, recurrent, or metastatic cervical cancer: Subgroup analyses of COMPASSION-16.卡度尼利单抗联合含铂化疗±贝伐珠单抗治疗持续性、复发性或转移性宫颈癌：COMPASSION-16 亚组分析汇报者：吴小华丨复旦大学附属肿瘤医院摘要号：5509Nimotuzumab combined with chemotherapy in the first-line treatment for patients with stage IVB, recurrent or persistent cervical squamous cell carcinoma: A multi-center, randomized, double-blind, and controlled study.尼妥珠单抗联合化疗用于IVB期、复发性或持续性宫颈鳞癌一线治疗：一项多中心、随机、双盲、对照研究汇报者：Zexuan Liu丨中国医学科学院肿瘤医院摘要号：5510Primary results of a phase 2 study of cisplatin-sensitized radiation therapy and pembrolizumab for unresectable vulvar cancer.顺铂增敏放射治疗和帕博利珠单抗治疗不可切除外阴癌的II期研究的主要结果汇报者：Oladapo O. Yeku丨麻省总医院、哈佛医学院摘要号：5511Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for endometrial cancer: Longitudinal changes in circulating tumor DNA.度伐利尤单抗联合卡铂/紫杉醇，后续使用度伐利尤单抗±奥拉帕利作为子宫内膜癌的一线治疗：循环肿瘤DNA的纵向变化汇报者：Shannon Neville Westin丨德克萨斯大学MD安德森癌症中心摘要号：5512Phase 2 study of letrozole, abemaciclib, and metformin in estrogen receptor (ER)–positive recurrent endometrial cancer (EC).来曲唑、阿贝西利和二甲双胍治疗雌激素受体(ER)阳性复发性子宫内膜癌的II期研究汇报者：Panagiotis A. Konstantinopoulos丨丹娜—法伯癌症研究所摘要号：5513Safety and preliminary efficacy from a phase 1 study of INCB123667, a selective CDK2 inhibitor, in patients with advanced platinum-resistant and refractory ovarian cancer (OC).I期研究中选择性CDK2抑制剂INCB123667治疗晚期铂耐药/难治性卵巢癌患者的安全性和初步疗效汇报者：Domenica Lorusso丨Agostino Gemelli 大学医院基金会 IRCCS摘要号：5514A phase II trial of pembrolizumab and lenvatinib in recurrent or persistent clear cell ovarian carcinoma (NCT05296512).帕博利珠单抗和仑伐替尼治疗复发性或持续性透明细胞卵巢癌的II期试验汇报者：Joyce F. Liu丨丹娜—法伯癌症研究所摘要号：5515A phase I/II study of the safety and efficacy of intraperitoneal IMNN-001 in combination with neoadjuvant chemotherapy (NACT) of paclitaxel and carboplatin in patients newly diagnosed with advanced epithelial ovarian cancer (EOC): Updated survival analysis from OVATION-2 trial.评估腹膜内注射IMNN-001联合紫杉醇/卡铂新辅助化疗治疗新诊断晚期上皮性卵巢癌的安全性和有效性的I/II期研究：来自OVATION-2试验的最新生存分析汇报者：Premal H. Thaker丨华盛顿大学医学院摘要号：5516Safety and efficacy of BAT8006, a folate receptor α (FRα) antibody drug conjugate, in patients with platinum-resistant ovarian cancer: Update on the dose optimization/expansion cohort of BAT-8006-001-CR trial.叶酸受体α（FRα）抗体药物偶联物BAT8006用于铂耐药卵巢癌患者的安全性和有效性：BAT-8006-001-CR试验的剂量优化/扩展队列更新汇报者：张松灵丨吉林大学第一医院摘要号：5517（来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

ASCO会议临床结果临床3期

2025-04-03

·药事纵横

3期新药临床成功，股价暴涨逾100%

声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。近日，Corcept Therapeutics宣布其Relacorilant联合白蛋白结合型紫杉醇（nab-paclitaxel）治疗铂耐药卵巢癌患者的关键3期临床试验ROSELLA达到了改善无进展生存率的主要终点，这一结果由盲法独立中央审查（BICR）评估。基于这些发现，Corcept Therapeutics计划在2025年第3季度提交新药申请(NDA)，预计在2026/27年左右获得批准并推向市场。Truist Securities预测，到2035年，该药物的峰值销售额可能达到约8亿美元。此消息发布后（3月31日），公司股价涨幅最高逾110%，股价达到前所未有的里程碑。Relacorilant是一种口服治疗药物，是一种选择性糖皮质激素受体(GR)拮抗剂，通过与GR结合（但不与身体的其他激素受体结合）来调节皮质醇活性。除卵巢癌外，Corcept公司正在研究relacorilant在各种严重疾病中的作用，包括内源性皮质醇增多症（库欣综合征）和前列腺癌。此前，美国FDA已接受relacorilant用于治疗内源性高皮质醇症，又名库欣综合征的新药申请（NDA），PDUFA目标行动日期定为2025年12月30日。ROSELLA试验(ClinicalTrials.gov标识符：NCT05257408)在美国、欧洲、韩国、巴西、阿根廷、加拿大和澳大利亚的多个试验点招募了381名铂耐药卵巢癌患者。患者按 1:1 的比例随机分组，分别接受Relacorilant联合nab-paclitaxel治疗或仅接受nab-paclitaxel治疗。ROSELLA试验有两个主要终点——经盲态独立中心审查评估的无进展生存期（PFS-BICR）和总生存期（OS）。只要满足其中一个终点，即视为取得阳性结果。在ROSELLA试验中，与单独使用nab-paclitaxel治疗的患者相比，接受Relacorilant联合nab-paclitaxel治疗的患者疾病进展风险降低了30%（风险比：0.70；p值：0.008）。他们的中位PFS-BICR为6.5个月，而单独接受nab-paclitaxel治疗的患者为5.5个月。在对总体生存期（OS）的中期评估中，接受Relacorilant联合nab-paclitaxel治疗的患者OS显著改善，中位OS为16.0个月，而单独接受nab-paclitaxel治疗的患者为11.5个月（风险比：0.69；p值：0.012）。Relacorilant耐受性良好，未观察到新的安全信号。与公司2期试验的情况一样，两组的安全性和耐受性相当。ROSELLA的完整结果将在今年的医学会议上公布。该公司对铂耐药性卵巢癌患者进行的relacorilant第2期阶段试验结果于2023年6月在《临床肿瘤学杂志》上发表。25年多来，Corcept公司专注于皮质醇调节及其治疗多种严重疾病患者的潜力，已发现了1000多种专有选择性皮质醇调节剂和GR拮抗剂。科塞普特公司正在对皮质醇增多症、实体瘤、肌萎缩侧索硬化症（ALS）和肝病患者进行高级临床试验。2012年2月，该公司推出了Korlym®（米非司酮），这是美国食品药品监督管理局批准的第一种用于治疗内源性皮质醇增多症患者的药物。除Korlym（米非司酮）以外，Corcept还在开发新的选择性皮质醇调节剂。几款领先的在研药物已经进入临床，作为各种严重疾病的潜在治疗方法——库欣综合征、晚期卵巢癌、伴有皮质醇过量的肾上腺癌、前列腺癌、ALS（肌萎缩侧索硬化）和NASH（非酒精性脂肪性肝炎）等。2015年之后，Corcept Therapeutics 一直依靠Korlym的收入为运营提供资金。 2024年全年营收增长强劲,同比增长40%至6.75亿美元。净利润增长33%至1.41亿美元。尽管第四季度因药房合作伙伴运营问题面临挑战，公司仍继续保持其在皮质醇调节疗法领域的领先地位。截至2024年底，公司维持6.03亿美元的强劲现金储备。展望未来，Corcept预计2025年收入指引为9.00亿美元至9.50亿美元。参考资料：www.corcept.com-END-2025CMC-CHINA药博会 • 展位火热预定中！药事纵横投稿须知：稿费已上调，欢迎投稿各位朋友好，觉得本文对您有帮助，请随手点一下下方的在看，以便让你的朋友也能看到哦。

临床结果临床3期临床2期临床成功

2025-04-03

·癌度

《癌度早报2025年4月3日》

癌度临床试验病友交流群（点击）一、新药快讯1、国产口服KRAS基因G12D靶向药获批临床2025年4月1日，CDE官网显示，国产一类抗癌药HBW-012336获批临床，用于携带 KRAS G12D 突变的局部晚期或转移性实体瘤，这是该药在国内首次获批临床试验阶段，之前模型试验发现，HBW-012336 表现出显著的抗肿瘤药效，而且该药还可以与EGFR蛋白抗体药物西妥昔单抗协同使用，具有协同增效作用。2、ROS1靶向药他雷替尼疗效数据公布2025年欧洲肺癌大会上，在国内获批用于ROS1阳性肺癌的他雷替尼对比克唑替尼的研究数据公布，他雷替尼的治疗应答率达到了71.7%，而克唑替尼的治疗应答率为57.7%，与克唑替尼相比，他雷替尼使疾病进展风险降低52%，死亡风险降低66%，并且具有统计学显著意义。 3、国内首款实体瘤细胞疗法申报上市2025年4月1日，中国国家药监局药品审评中心（CDE）官网最新公示，爱可仑赛注射液上市申请获得受理。这是一种广谱性的细胞免疫治疗产品，为针对实体瘤的CIK疗法，该药在今年3月份被正式纳入优先审评，拟定的适应症为高复发风险的原发性肝细胞癌术后复发预防。二、新药快讯1、前沿药Relacorilant联合白蛋白紫杉醇，有效控制卵巢癌病情根据一项三期人体临床试验结果，前沿药Relacorilant联合白蛋白紫杉醇，相比单用白蛋白紫杉醇，在铂耐药卵巢癌患者中，显著改善了无进展生存时间，将中位无进展生存时间从5.5个月延长到6.5个月，将中位总生存时间从11.5个月延长到16个月，相比对照组，上述联合用药将疾病进展或死亡风险降低了30%。

优先审批临床3期免疫疗法细胞疗法申请上市

100 项与 Relacorilant 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11336	Relacorilant	-	DB14976

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
库欣综合征	申请上市	美国	Corcept Therapeutics, Inc.	2024-12-30
内源性库欣综合征	临床3期	意大利	Corcept Therapeutics, Inc.	2018-11-15
内源性库欣综合征	临床3期	荷兰	Corcept Therapeutics, Inc.	2018-11-15
内源性库欣综合征	临床3期	加拿大	Corcept Therapeutics, Inc.	2018-11-15
内源性库欣综合征	临床3期	西班牙	Corcept Therapeutics, Inc.	2018-11-15
内源性库欣综合征	临床3期	以色列	Corcept Therapeutics, Inc.	2018-11-15
内源性库欣综合征	临床3期	奥地利	Corcept Therapeutics, Inc.	2018-11-15
内源性库欣综合征	临床3期	美国	Corcept Therapeutics, Inc.	2018-11-15
内源性库欣综合征	临床3期	保加利亚	Corcept Therapeutics, Inc.	2018-11-15
内源性库欣综合征	临床3期	波兰	Corcept Therapeutics, Inc.	2018-11-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03776812 (CTgov)	临床2期	复发性铂耐药性原发性腹膜癌 \| 复发性卵巢癌 \| 复发性原发性腹膜癌 \| 输卵管癌	178	Nab-paclitaxel+Relacorilant (Arm A: Continuous Relacorilant Dosing)	(衊餘蓋繭觸選壓衊鹽淵) = 齋繭憲觸築鹽獵遞艱簾夢鹹憲製範鹹願糧顧襯 (積艱積齋鹽艱積顧構構, 衊憲廠構範遞製網觸願 ~ 鏇顧獵積選構積醖網鏇) 更多	-	2025-04-30
				Nab-paclitaxel+Relacorilant (Arm B: Intermittent Relacorilant Dosing)	(衊餘蓋繭觸選壓衊鹽淵) = 簾衊鏇繭觸鬱鏇遞膚壓夢鹹憲製範鹹願糧顧襯 (積艱積齋鹽艱積顧構構, 餘簾淵鏇簾鏇鏇窪齋夢 ~ 廠鑰衊襯蓋繭廠遞鏇觸) 更多
NCT03697109 (GRACE, CTgov)	临床3期	内源性库欣综合征	152	Relacorilant (Relacorilant (RW Phase))	(衊築夢觸鑰襯淵願獵簾) = 艱製壓淵鏇鹹鏇淵廠範範選鏇齋窪築網構鬱鹽 (窪願觸願餘構憲鹽顧選, 積積簾築繭鏇襯淵積簾 ~ 願鬱選憲淵壓壓鬱鬱積) 更多	-	2025-04-24
				Placebo (Placebo (RW Phase))	(衊築夢觸鑰襯淵願獵簾) = 鬱簾膚餘築鹹鬱齋夢繭範選鏇齋窪築網構鬱鹽 (窪願觸願餘構憲鹽顧選, 顧鑰襯壓鬱觸鏇憲鹽繭 ~ 糧襯夢窪襯鹽網繭願繭) 更多
NCT05257408 (ROSELLA, Company_Website) 人工标引	临床3期	铂耐药性卵巢癌	381	Relacorilant + nab-paclitaxel	(襯遞鑰廠糧觸壓夢憲壓) = 蓋膚憲鹹製簾願觸構醖淵壓糧艱膚鹹鑰衊蓋壓 (積構築範醖鹹齋廠糧鹹 ) 达到更多	积极	2025-03-31
				Nab-paclitaxel	(襯遞鑰廠糧觸壓夢憲壓) = 廠範遞醖鹽鑰淵築襯膚淵壓糧艱膚鹹鑰衊蓋壓 (積構築範醖鹹齋廠糧鹹 ) 达到更多
NCT03604198 (BusinessWire) 人工标引	临床3期	库欣综合征	116	Relacorilant	(夢願夢壓膚醖獵廠膚觸) = At month 24 of the study, patients exhibited clinically meaningful and statistically significant reductions in mean systolic blood pressure (10.0 mm Hg; p-value: 0.012) and mean diastolic blood pressure (7.3 mm Hg; p-value: 0.016), compared to their measurement at entry into the long-term extension study. 顧壓窪鏇鹹淵繭襯選鏇 (衊築齋窪鑰壓顧襯糧鹽 ) 更多	积极	2024-12-16
NCT03604198 (Company_Website) 人工标引	临床2期	库欣综合征	53	Relacorilant	(顧鬱憲範艱選製繭願鬱) = 簾網糧觸願製鑰憲製製艱網範範網糧範鑰醖衊 (獵壓艱廠鑰鬱艱醖觸鏇 ) 更多	积极	2024-11-25
NCT04308590 (GRADIENT, Biospace) 人工标引	临床3期	库欣综合征	137	relacorilant	(鑰襯夢襯繭製積顧遞淵) = 齋蓋廠糧選遞製網壓獵膚網遞憲觸膚壓築網壓 (壓壓襯願壓糧觸糧網積 ) 达到	积极	2024-10-30
				Placebo	(鑰襯夢襯繭製積顧遞淵) = 繭蓋膚蓋艱窪醖憲醖觸膚網遞憲觸膚壓築網壓 (壓壓襯願壓糧觸糧網積 ) 达到
NCT02804750 \| NCT00280475 (Pubmed \| J Endocrinol Invest)	临床2期	库欣综合征 factor VIII \| activated partial thromboplastin time \| platelet count ... 更多	34	Relacorilant (Surgery)	(廠壓鬱積築鹹鏇範願網) = 醖觸膚衊衊膚繭鹹餘壓糧繭蓋鏇構衊獵窪網艱 (鑰醖鬱鑰齋鬱糧膚鹽鬱 )	积极	2024-09-21
NCT03697109 (GRACE, ENDO2024)	临床3期	库欣综合征	152	Relacorilant 100 mg QD	獵淵窪夢襯鏇構鏇餘構(鏇襯衊鬱選製醖構醖積) = 願網壓網衊築壓夢壓窪選壓夢憲艱簾選衊襯簾 (鏇鹹窪淵艱築蓋鏇選製, 6.7) 更多	积极	2024-06-01
NCT03697109 (GRACE, Company_Website) 人工标引	临床3期	库欣综合征	-	relacorilant	(鹹齋鹹醖廠鏇鏇簾齋膚) = GRACE met its primary endpoint of loss of blood pressure control in the randomized withdrawal phase among patients receiving relacorilant as compared to placebo 製廠選簾淵淵簾簾網鹹 (築膚衊襯製鑰夢構鹹夢 ) 达到更多	积极	2024-05-28
				placebo
NCT03697109 (GRACE, GlobeNewswire) 人工标引	临床3期	内源性库欣综合征	152	relacorilant	(製餘壓夢餘襯觸鹹壓夢) = 鏇網獵窪鏇鹽鬱築鬱範廠糧廠顧鑰獵膚繭窪築 (淵築糧膚淵廠選鏇襯窪 ) 更多	积极	2024-04-22
				relacorilant (withdrawal phase)	(製餘壓夢餘襯觸鹹壓夢) = 積窪網廠選齋積觸構鏇廠糧廠顧鑰獵膚繭窪築 (淵築糧膚淵廠選鏇襯窪 ) 更多